Please login to the form below

Not currently logged in
Email:
Password:

Biogen's Douglas Williams departs for biotech start-up

Research head will be first member of a new cancer-focused firm

Biogen Douglas WilliamsDouglas Williams will this week leave Biogen for a new role as CEO of an as-yet unnamed biotech start-up that will focus on cancer diagnostics and therapies.

Williams had led Biogen's R&D  since 2011 as executive vice president of research and development, prior to which his industry roles included a six year stint at Seattle-based biotech Zymogenetics (now part of BMS), where he rose to be its CEO.

He said: “While I am sad to leave Biogen I am excited about the opportunity to follow a real passion of mine. I am proud of the progress of the company's R&D organisation and am pleased that it will be in very capable hands.”

Williams will be replaced by chief medical officer Alfred Sandrock and chief scientific officer Spyros Artavanis-Tsakonas, who will be handed joint responsibility for Biogen Research and Development.

Biogen's CEO George Scangos said: “All of us at Biogen appreciate Doug's contributions to the rapid development of our Research and Development organisation.

“We are fortunate to have Al Sandrock and Spyros Artavanis-Tsakonas to lead the work to which Biogen is dedicated.”

27th July 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Webinar: Usability and UX: You’ve been asked to test...What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
...

Infographics